JFS Wealth Advisors LLC Sells 583 Shares of Kenvue Inc. (NYSE:KVUE)

JFS Wealth Advisors LLC lowered its stake in shares of Kenvue Inc. (NYSE:KVUE) by 16.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,978 shares of the company’s stock after selling 583 shares during the quarter. JFS Wealth Advisors LLC’s holdings in Kenvue were worth $64,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. Grove Bank & Trust raised its position in Kenvue by 438.4% in the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after purchasing an additional 947 shares in the last quarter. Geneos Wealth Management Inc. bought a new position in shares of Kenvue in the 4th quarter valued at about $29,000. Fortitude Family Office LLC raised its stake in shares of Kenvue by 106.6% during the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after buying an additional 777 shares during the last quarter. Ashton Thomas Securities LLC acquired a new position in Kenvue in the third quarter valued at approximately $35,000. Finally, Versant Capital Management Inc boosted its stake in Kenvue by 300.8% in the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock valued at $41,000 after acquiring an additional 1,441 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Performance

Shares of Kenvue stock opened at $22.00 on Wednesday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The firm has a market cap of $42.17 billion, a price-to-earnings ratio of 41.50, a price-to-earnings-growth ratio of 2.16 and a beta of 1.45. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46. The stock’s 50-day moving average is $21.30 and its 200-day moving average is $22.12.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Equities analysts predict that Kenvue Inc. will post 1.05 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.73%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is currently 154.72%.

Analyst Ratings Changes

Several research analysts have recently issued reports on KVUE shares. Piper Sandler upgraded Kenvue from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $21.00 to $26.00 in a research report on Monday, January 6th. Citigroup decreased their target price on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Wednesday, January 15th. Canaccord Genuity Group cut their price target on shares of Kenvue from $27.00 to $24.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Barclays lowered their target price on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research note on Friday, January 17th. Finally, UBS Group reduced their price target on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $23.00.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.